Group | All SIC | HMW | LMW | ||||||
Low bronchial calibre* | Low bronchial calibre* | Low bronchial calibre* | |||||||
Yes | No | Total | Yes | No | Total | Yes | No | Total | |
Low nasal airway patency† | |||||||||
Yes | 13 | 12 | 25 | 11 | 4 | 15 | 2 | 8 | 10 |
No | 4 | 14 | 18 | 4 | 3 | 7 | 0 | 11 | 11 |
Total | 17 | 26 | 43 | 15 | 7 | 22 | 2 | 19 | 21 |
RR (95% CI) | 1.7 (1.0 to 2.4) | 1.3 (0.8 to 2.7) | 2.4 (0.7 to 2.4) | ||||||
p Value | 0.04 | 0.6 | 0.2 |
CI, confidence interval; HMW, high molecular weight; LMW, low molecular weight; RR, risk ratio.
*Clinically significant: decrease in FEV1 ⩾20% from baseline after challenge.
†Clinically significant: decrease in Vol2–5 ⩾30% from baseline after challenge.
p Value by χ2 and Fisher exact tests when appropriate.